Wednesday, January 26, 2011

Molecular Diagnostics in Infectious Disease Testing

New report loaded today - are you interested in infectious disease diagnostics? This 300+ page report will be for you access this report now.

In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing.

The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include:

1) the existing and emerging technologies in the field

2) the U.S. and global market size for molecular diagnostic products

3) the profiles of companies that are focusing on the molecular diagnostic sector.

The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts.


Blogger Moshe Sharon said...

With the advent of new medical technology called Molecular Diagnostics, we have a new double edged sword for the new world order. While DNA and RNA analysis will prove useful in reducing medical costs and take the guess work out of prescribing drugs, there is the danger of DNA profiles being used in the nefarious new world order conspiracy for domination and control.

2:25 AM  
Blogger Jon Goldhill said...

A little paranoid maybe but you do have a point especially when it comes to insurance coverage. If insurance companies insist on molecular profiling this could lead to the most at risk patients being placed on higher premiums. I understand that this is controled legally in the US but I am not sure.

7:15 AM  

Post a Comment

<< Home